Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proteogenomics | 12 | 2024 | 102 | 4.670 |
Why?
|
| Proteomics | 16 | 2025 | 586 | 3.610 |
Why?
|
| Neoplasms | 10 | 2025 | 3007 | 2.220 |
Why?
|
| Proteome | 7 | 2025 | 280 | 1.790 |
Why?
|
| Antigens, Neoplasm | 5 | 2024 | 404 | 1.710 |
Why?
|
| Algorithms | 6 | 2025 | 1728 | 1.520 |
Why?
|
| Machine Learning | 2 | 2025 | 327 | 1.440 |
Why?
|
| Liver Neoplasms | 4 | 2024 | 1407 | 1.260 |
Why?
|
| Phosphoproteins | 3 | 2025 | 452 | 1.030 |
Why?
|
| Phosphopeptides | 2 | 2023 | 28 | 0.970 |
Why?
|
| Peptides | 6 | 2024 | 861 | 0.900 |
Why?
|
| Genomics | 5 | 2023 | 1668 | 0.890 |
Why?
|
| Neoplasm Proteins | 5 | 2021 | 715 | 0.870 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2025 | 382 | 0.860 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2023 | 279 | 0.860 |
Why?
|
| Data Mining | 1 | 2023 | 57 | 0.830 |
Why?
|
| Phosphorylation | 9 | 2025 | 1698 | 0.830 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2023 | 996 | 0.830 |
Why?
|
| PubMed | 2 | 2023 | 23 | 0.830 |
Why?
|
| Bayes Theorem | 1 | 2024 | 315 | 0.820 |
Why?
|
| Natural Language Processing | 1 | 2023 | 65 | 0.820 |
Why?
|
| Computational Biology | 3 | 2025 | 886 | 0.820 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2023 | 113 | 0.810 |
Why?
|
| Colorectal Neoplasms | 3 | 2021 | 650 | 0.640 |
Why?
|
| Search Engine | 1 | 2018 | 7 | 0.620 |
Why?
|
| Publications | 1 | 2018 | 36 | 0.610 |
Why?
|
| Information Storage and Retrieval | 1 | 2018 | 65 | 0.600 |
Why?
|
| Biomedical Research | 1 | 2023 | 556 | 0.550 |
Why?
|
| Proteins | 1 | 2023 | 1086 | 0.550 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 1848 | 0.530 |
Why?
|
| Peptide Hydrolases | 1 | 2017 | 151 | 0.530 |
Why?
|
| Mass Spectrometry | 3 | 2023 | 368 | 0.510 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1711 | 0.490 |
Why?
|
| Alternative Splicing | 1 | 2017 | 373 | 0.470 |
Why?
|
| Humans | 29 | 2025 | 133540 | 0.430 |
Why?
|
| Molecular Targeted Therapy | 3 | 2024 | 407 | 0.370 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2024 | 2111 | 0.360 |
Why?
|
| Endometrial Neoplasms | 2 | 2023 | 114 | 0.340 |
Why?
|
| Software | 3 | 2025 | 735 | 0.340 |
Why?
|
| Precision Medicine | 3 | 2023 | 358 | 0.290 |
Why?
|
| Databases, Protein | 2 | 2025 | 62 | 0.280 |
Why?
|
| Substrate Specificity | 2 | 2025 | 310 | 0.270 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 3719 | 0.270 |
Why?
|
| Protein Kinases | 2 | 2025 | 342 | 0.250 |
Why?
|
| HLA-A2 Antigen | 1 | 2024 | 27 | 0.230 |
Why?
|
| Benchmarking | 2 | 2025 | 149 | 0.230 |
Why?
|
| Protein Interaction Maps | 1 | 2024 | 89 | 0.220 |
Why?
|
| Knowledge Bases | 1 | 2023 | 39 | 0.210 |
Why?
|
| Cloud Computing | 1 | 2023 | 14 | 0.210 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2023 | 90 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 178 | 0.210 |
Why?
|
| Datasets as Topic | 1 | 2023 | 104 | 0.200 |
Why?
|
| Protein Isoforms | 1 | 2023 | 426 | 0.190 |
Why?
|
| HLA Antigens | 1 | 2023 | 251 | 0.190 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 396 | 0.190 |
Why?
|
| Metformin | 1 | 2023 | 162 | 0.180 |
Why?
|
| Immunotherapy | 2 | 2024 | 743 | 0.180 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2020 | 48 | 0.170 |
Why?
|
| RNA | 1 | 2023 | 600 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 166 | 0.160 |
Why?
|
| Gene Expression Profiling | 3 | 2023 | 1905 | 0.160 |
Why?
|
| Systems Biology | 1 | 2019 | 63 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 132 | 0.160 |
Why?
|
| Transcriptome | 3 | 2021 | 1121 | 0.150 |
Why?
|
| Databases, Factual | 1 | 2023 | 1245 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 2766 | 0.150 |
Why?
|
| Signal Transduction | 4 | 2025 | 4879 | 0.150 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2018 | 198 | 0.140 |
Why?
|
| DNA | 1 | 2023 | 1665 | 0.140 |
Why?
|
| Prognosis | 3 | 2023 | 5064 | 0.140 |
Why?
|
| Disease | 1 | 2018 | 134 | 0.140 |
Why?
|
| Carcinoma | 1 | 2020 | 317 | 0.140 |
Why?
|
| Mutation | 4 | 2024 | 6260 | 0.130 |
Why?
|
| Cell Line | 1 | 2021 | 2833 | 0.130 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 269 | 0.130 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 399 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 709 | 0.120 |
Why?
|
| Internet | 1 | 2018 | 398 | 0.120 |
Why?
|
| Gene Expression | 1 | 2020 | 1612 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 733 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 875 | 0.120 |
Why?
|
| Exons | 1 | 2017 | 833 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 843 | 0.120 |
Why?
|
| Autism Spectrum Disorder | 1 | 2020 | 421 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 1065 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1793 | 0.090 |
Why?
|
| Acetylation | 2 | 2021 | 182 | 0.080 |
Why?
|
| Neurons | 1 | 2020 | 2034 | 0.080 |
Why?
|
| Glycolysis | 2 | 2021 | 171 | 0.080 |
Why?
|
| Mice | 3 | 2021 | 18808 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2021 | 248 | 0.080 |
Why?
|
| Brain | 1 | 2020 | 3211 | 0.070 |
Why?
|
| Female | 7 | 2023 | 71524 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 7202 | 0.060 |
Why?
|
| Animals | 3 | 2021 | 36266 | 0.060 |
Why?
|
| beta Catenin | 1 | 2023 | 225 | 0.050 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2021 | 20 | 0.050 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2021 | 35 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 50 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 67 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2021 | 179 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 508 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2025 | 608 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2023 | 6654 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 436 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2020 | 71 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2021 | 456 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 43 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2021 | 303 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2020 | 238 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2021 | 380 | 0.040 |
Why?
|
| Serotonin | 1 | 2020 | 223 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2019 | 86 | 0.040 |
Why?
|
| Aged | 3 | 2021 | 21701 | 0.040 |
Why?
|
| Genomic Instability | 1 | 2020 | 242 | 0.040 |
Why?
|
| Social Behavior | 1 | 2020 | 230 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2021 | 538 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2017 | 110 | 0.030 |
Why?
|
| Protein Binding | 1 | 2021 | 1831 | 0.030 |
Why?
|
| Middle Aged | 3 | 2021 | 29347 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 442 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 230 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 773 | 0.030 |
Why?
|
| Adult | 3 | 2021 | 31933 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2017 | 313 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2017 | 198 | 0.030 |
Why?
|
| Male | 4 | 2021 | 65774 | 0.030 |
Why?
|
| Genome, Human | 1 | 2021 | 1348 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1731 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 733 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2020 | 947 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 679 | 0.020 |
Why?
|
| Apoptosis | 1 | 2019 | 1929 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 5177 | 0.020 |
Why?
|
| Models, Biological | 1 | 2017 | 1531 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 4523 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2019 | 2537 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4742 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2935 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2023 | 13001 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 9899 | 0.020 |
Why?
|